New Analysis Raises Annual Nonmelanoma Skin Cancer Diagnoses to 4.7 Million in the U.S.

A new analysis estimates that 4.7 million Americans are diagnosed with nonmelanoma skin cancer each year, 42% more than previously reported, highlighting the need for better tracking and awareness of treatment options.

Houston Metrowire Staff
••Healthcare
New Analysis Raises Annual Nonmelanoma Skin Cancer Diagnoses to 4.7 Million in the U.S.

The most common cancer in the United States is more widespread than previously believed. A new analysis by SkinCure Oncology suggests that approximately 4.7 million Americans are diagnosed with nonmelanoma skin cancer (NMSC) annually, a 42 percent increase over the long-cited figure of 3.3 million. That equates to nearly 13,000 new diagnoses every day.

The earlier estimate, which had been repeated by healthcare organizations for more than a decade, stemmed from research published in 2015 using data collected in 2012. The updated analysis accounts for significant demographic shifts since then. The U.S. population aged 65 and older has grown nearly 50 percent, reaching roughly 64 million in 2026, and older Americans are disproportionately affected by NMSC. The new estimate also incorporates historical growth in diagnoses and independent federal healthcare survey data.

NMSC includes basal cell carcinoma and squamous cell carcinoma, the two most common forms of skin cancer. While highly treatable when detected early, the disease can cause significant tissue damage, disfigurement, and, in some cases, life-threatening complications. Despite its prevalence, the United States lacks a comprehensive national system for tracking NMSC cases, which experts say hampers prevention and treatment efforts.

“Skin cancer deserves far more attention than it receives,” said Kerwin Brandt, CEO of SkinCure Oncology. “Accurate information about the millions of Americans affected each year is essential to improving prevention, early detection, access to treatment and patient outcomes.” The company is calling for the establishment of a national database to track the disease.

As the number of diagnoses has grown, treatment options have also advanced. Surgery, including Mohs micrographic surgery, remains an effective and widely used approach, but for appropriate patients, nonsurgical alternatives offer equally impressive results with no cutting, pain, or need for subsequent cosmetic surgery. One established approach, Image-Guided Superficial Radiation Therapy (IGSRT), combines low-energy X-rays with high-resolution ultrasound imaging to treat skin cancer without surgery. Published clinical studies involving thousands of early-stage lesions have reported local control rates exceeding 99 percent.

GentleCure®, offered through participating dermatology practices by SkinCure Oncology, incorporates IGSRT into a comprehensive, cancer center-level model of care delivered in the dermatologist’s office. Despite such advances, many patients still don’t learn about nonsurgical alternatives unless they ask. “Patients deserve to know all their treatment options,” Brandt said. “Our goal is to ensure patients fully understand their options, and encourage them to work with their physicians to select the optimum approach.”

For more information about nonsurgical skin cancer treatment options, and to find the nearest provider of the GentleCure Experience℠, visit GentleCure.com. The announcement underscores the growing burden of skin cancer and the importance of accurate data and informed treatment decisions.

Blockchain Registration

QR Code for Blockchain Registration